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Abstract
Purposes: The aim of this study was to evaluate the prevalence of drug-induced gingival 
overgrowth (DIGO) in Brazilian users of nifedipine and/or phenytoin and to determine the 
presence of predisposing/modifying factors.
Methods: Demographic, pharmacological, and periodontal data were obtained from 100 
users of the Brazilian Primary Health Care System in Diamantina, Jequitinhonha Valley, Minas 
Gerais state, Brazil, who were taking nifedipine and/or phenytoin. Clinical evaluations including 
gingival overgrowth analysis were carried out by a single calibrated examiner. Bivariate analysis 
(Chi-square test or Student’s t-test) were used to identify demographic, periodontal and drug-
related significant factors associated with gingival overgrowth severity. Multivariate analysis 
(Poisson regression) was used to assess confounding factors.
Results: The prevalence of DIGO was high (86%), but its severity was predominately mild. 
The prevalence of DIGO was significantly higher in phenytoin users than in nifedipine users 
(p=0.01). There was no association between DIGO and demographic, pharmacological or 
periodontal variables.
Conclusion: The high occurrence of DIGO among users of nifedipine and phenytoin emphasizes 
the importance of the dentist as part of the public health team to provide the prevention, early 
diagnostic, and control of this alteration.
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Resumo
Objetivo: Avaliar a prevalência dos aumentos gengivais medicamentosos em usuários brasileiros 
de nifedipina e fenitoína e determinar a presença de fatores preditores/modificadores.
Metodologia: Dados demográficos, farmacológicos e periodontais foram obtidos de 100 
pacientes usuários da Atenção Primária no Vale do Jequitinhonha que usavam nifedipina   
e/ou fenitoína. Avaliações clínicas, incluindo a análise do aumento gengival, foram feitas 
por um avaliador calibrado. Análises bivariadas (teste do qui-quadrado ou teste t de Student) 
foram usadas para identificar fatores demográficos, periodontais e medicamentosos que 
apresentassem associação com a severidade do aumento gengival. Foi utilizada análise 
multivariada (regressão de poisson) para estimar a razão de prevalência e intervalo de 95% 
de confiança para identificar os fatores de risco associados ao desenvolvimento do AG.
Resultados: A prevalência do aumento gengival foi elevada (86%), mas a gravidade mais 
comumente observada foi a leve. A prevalência foi maior em usuários de fenitoína do 
que de nifedipina (p=0.01). Não houve associação entre aumento gengival e as variáveis 
demográficas, farmacológicas e periodontais.
Conclusão: A alta prevalência do aumento gengival medicamentoso entre os usuários de 
nifedipina e fenitoína enfatiza a importância do cirurgião dentista no diagnóstico, prevenção 
e controle dessa alteração.
Palavras-chave: Nifedipina; fenitoína; hiperplasia gengival; atenção primária em saúde
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Introduction
Several systemic diseases and medications used to treat these 
conditions may influence oral health status (1). Drug-induced 
gingival overgrowth (DIGO) is the main side effect in the 
oral cavity among users of nifedipine, a beta-blocker of 
calcium channels, and phenytoin, an anti-seizure drug (2,3). 
DIGO frequently begins during the first 3 months after 
medication, with variable extent, from small alterations in 
the gingival papilla to total coverage of the dental crown. It 
is more conspicuous in the buccal than in the lingual gingiva 
and less severe in the maxilla than in the mandible (4,5). 
DIGO may lead to esthetic and/or functional alterations, 
impairing occlusion, mastication and speech (2,6). It also 
impairs dental hygiene, resulting in a higher susceptibility 
to caries and periodontal diseases (6). The prevalence of this 
DIGO is widely variable (2), but large controlled studies have 
revealed a percentage of 50% for phenytoin users, and 6 to 
83% for nifedipine users (2,7). Furthermore, several factors, 
including  age,  genetic  predisposition,  pharmacokinetic 
variables, dental biofilm accumulation and drug-induced 
activation of cytokines have been suggested to influence the 
development of DIGO (8).
There is a substantial knowledge about the clinical features 
of DIGO; however, there is a paucity of epidemiological 
studies involving DIGO in the Brazilian population. The 
Brazilian Primary Health Care System service represents 
the patient’s first contact with the health public care system, 
and is especially responsible for the attendance of patients 
with chronic diseases. The Brazilian Primary Health Care 
System also provides pharmaceutical assistance to low 
income patients, offering indispensable drugs to control 
chronic diseases, including nifedipine and phenytoin (9). 
The aim of this study was to evaluate the prevalence of DIGO 
among Brazilian patients who were prescribed nifedipine or 
phenytoin through the program of pharmaceutical assistance 
of  the  Brazilian  Primary  Health  Care  System,  and  to 
comprehend its clinical characteristics and risk factors.
Methodology
This descriptive and cross-sectional study was conducted 
across the population basis, according to ethical principles in 
human research and was approved by the Ethical Committee 
of State University of Montes Claros (678/2007). This 
survey was conducted in Diamantina, a municipality in the 
Jequitinhonha Valley of the Brazilian State of Minas Gerais, 
one of the poorest regions in Brazil (total population of 
44,746) (21). Using the records of the Brazilian Primary 
Health Care System, the initial number of patients listed 
for participation in the study was 395 individuals. However, 
losses occurred due to factors such as missing address, 
migration, death and drug discontinuity (112 patients were 
totally edentulous, 37 had interrupted the use of the drugs, 
21 had already died, 13 patients refused to participate, 27 
had moved to another city and 85 were not found at the 
registered addresses).
Thus, a total of one hundred patients (62 nifedipine users, 
37 pheynitoin users and one user of both nifedipine and 
phenythoin)  comprised  this  analysis.  Exclusion  criteria 
included patients aged less than eleven years, and patients 
who referred irregular utilization or less than three months 
of drug initiation. Patients presenting less than four anterior 
inferior or superior teeth and co-users of other drugs that 
result in gingival overgrowth were also excluded. 
Patients  were  contacted  at  their  homes  and  invited  to 
participate in the study. Those who agreed to participate 
signed  a  consent  form  and  responded  to  an  interview 
conducted by one previously trained investigator. After 
the interview, the researcher-examiner held the clinical 
intra-oral examination. All patients were examined with 
appropriate instruments (periodontal probe, clinical mirror 
and wooden spatula), in ideal conditions of biosecurity and 
under artificial lighting.
Demographic  data,  including  gender,  age,  profession, 
monthly income, scholarship level, complete medical history 
including past and actual diseases, drugs, concentrations, 
posology and time of treatment were considered and listed for 
each patient, through individual interviews (questionnaire). 
Patients were asked about their perception of any change in 
their gums, and if so were asked if they sought professional 
assistance for the problem.
Gingival and Periodontal Conditions
The gingival and periodontal conditions were accessed by 
a single-blinded examiner (intra-examiner agreement tested 
by means of Kappa test, Kappa= 0.85). Gingival overgrowth 
and dental biofilm evaluation was performed and restricted 
to twelve anterior/superior teeth. The following parameters 
were used:
1.  Index to evaluate the periodontal condition – Community 
Periodontal Index (CPI), (20,26) according to the criteria 
established in the 4th edition of the Basic Survey of Oral 
Health of the World Health Organization and in a national 
oral health survey (SB Brasil) conducted in 2002–2003 
by the Brazilian Health Ministry.
2.  Plaque Index (13) – Evaluated the presence/absence of 
biofilm by the dual count. After the calculated count for 
each patient, the percentage of teeth with biofilm was 
categorized on a scale of four points.
3.  Gingival Overgrowth Index (10) – The gingival over- 
growth was evaluated clinically in each patient using 
a scale of four points (0=without overgrowth, 1=mild 
overgrowth without dental crown involvement, 2=mode- 
rate  overgrowth  with  increased  interdental  papilla 
and slight increase over the dental crown, 3=evident 
overgrowth involving the crown surface). In the absence 
of teeth, the adjacent dental papilla of the edentulous area 
was considered in the classification. The patient´s score 
for tthis index was considered as the most prevalent in 
percentage. For the patients with grades 2 (moderate) or 
3 (severe overgrowth), surgical therapies were carried 
out. All patients were instructed about oral hygiene and 
received professional dental cleaning.144  Rev. odonto ciênc. 2010;25(2):142-147
Drug-induced gingival overgrowth
Statistical Analysis
Plaque índex, CPI and Gingival overgrowth index were 
calculated for each patient. The normality of the distribution 
of  these  variables  was  tested  thought  the  one-sample 
Kolmogorov-Sminorv test and was confirmed as normal. 
The  Gingival  overgrowth  index  was  re-categorized  in 
presence or absence. Chi-square test and Student t-test 
were used to identify the association between DIGO with 
demographic, periodontal and pharmacological features, 
thought a bivariate analysis. Multivariate analysis through 
the Poisson Regression was conducted to verify the DIGO 
associated risk factors. A 5% significance level was settled 
for all statistical analyses (P<0.05), except for the bivariate 
analysis (α=25%). 
Results
Demographic and medical variables
Among the 100 individuals, the age ranged from 11 to 81 
years (mean age of 46.8±15.1). Melanoderm individuals 
were more prevalent (44 (44%)). Due to a wide variation 
of professions that were referred to, these professions were 
categorized and the most common was identified as manual 
work (60%). Of all analyzed patients, 61% had not concluded 
basic education. A family income of less than the minimum 
wage was cited by the majority (67%). The most important 
demographic data are listed in Table 1.
With regard to the medical history of these individuals, the 
most prevalent diseases were arterial hypertension (63%), 
followed  by  neuropsychiatry  disturbances  (28%).  The 
majority of individuals were under medical follow up (82%), 
and utilized the SUS units (67%). The other 33% utilized, 
simultaneously, private health units.
Phamacological Variables
Nifedipine users comprised 62% of the evaluated sample, 
followed by phenytoin users (37%) and one patient used both 
medications. Only 5 individuals (5%) had been using these 
drugs for three months to one year, 29 (29%) for one year to 
three years and 65% for more than three years. Demographic 
data and drug utilization are shown in Table 2.
Periodontal Variables
Gingival  overgrowth  was  considered  mild  in  54(54%) 
individuals, moderate in 30 (30%) and severe in 2 (2%). 
Although the prevalence of DIGO in both groups reached 
86% (P=0.01), 71 individuals (71%) did not perceive any 
gingival alterations. Of the individuals who perceived the 
DIGO, 15 (51.72%) did not seek dental care.
Considering the groups alone, the prevalence of DIGO 
associated with nifedipine was 79% among users of this drug 
and 97.3% among the users of phenytoin. The mild DIGO 
was more prevalent in both groups [nifedipine (51.6%) and 
phenytoin (56.8%)]. The majority presented an elevated 
level of dental plaque (76 to 100% of examined teeth), 
61.2% being nifedipine users and 54% phenytoin users. 
Regarding the periodontal condition of these individuals, 
periodontal pockets of 4 to 5 mm and dental calculus were 
largely found in both groups. The periodontal condition data 
are presented in Table 3.
Table 1. Distribution of individuals in treatment with phenynoin 
or/and nifedipine, according to general demographic data 
(n=100).
Variable Category n %
Gender Male 49 49
Female 51 51
Skin Color Melanoderm 44 44
Feoderm 43 43
Leucoderm 13 13
Profession Retired, without defined 
profession, or student
25 25
Manual job 60 60
Non-manual job 15 15
Schooling
Level
Illiterate 8 8
1st grade incomplete 61 61
1st grade complete 15 15
2nd gradecomplete 13 13
3th grade complete 3 3
Monthly Family 
Income
Up to one minimum wage 67 67
One to two  minimum wages 22 22
More than two  minimum wages 11 11
Nifedipine
n              %
Phenytoin
n              %
Nifedipine and 
Phenytoin
n              %
Number of patients
Males
Females
62             62
30             30
32             32
37             37
18             18
19             19
0             01
Mean age (years) 53 37
Variation (min – max) (27-76) (11-81)
Standard doses 30-60 mg/day 100-300 mg/day
Mean doses 41 mg/day 180 mg/day
Variation (min-max) (20-100 mg/day) (25-400 mg/day)
Time of utilization (months-mean) 68 129
Variation (min-max) (12-240) (4-516)
Table 2. Distribution of patients, 
according to demographic and 
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The bivariate analysis identified monthly family income   
(P=0.04), source of medication (P=0.01), the drug con- 
centration (P=0.022) and treatment duration (P=0.194)   
as predictor factors associated with gingival overgrowth 
Variable Without overgrowth With overgrowth  P
Age 51.4±3.6 46.12±1.6 0.23*
Gender
Male (%)
Female (%)
7
7
42
44
0.94
Family Income
Up to one  minimum wage (%)
More than one  minimum  wage(%)
6
8
60
25
0.041*
Profession
Without occupation or retired (%)
Professionally active (%)
2
12
22
63
0.34
Schooling
Illiterate (%)
Non Illiterate (%)
1
13
7
79
0.89
Type of drug
Nifedipine (%)
Phenytoin (%)
Both
13
1
0
49
36
1
0.01*
Concentration
Nifedipine Pattern
Phenytoin Pattern
Over than Nifedipine Pattern
12
1
1
40
37
8
0.022*
Doses
Low
Medium
High
3
10
1
21
48
16
0.48
Time of treatment
Up to three years
Over three years
7
7
27
57
0.194*
Plaque Index
0 to 50%
51 to 75%
76 to 100%
3
4
7
16
18
52
0.74
CPI
Without alteration
Calculus and bleeding
Periodontal Pockets
1
8
5
7
42
36
0.866
Variable Category Nifedipine
n=62  /  n %
Phenytoin
n=37  /  n %
Gingival Overgrowth Absent   13 21   1 2.7
Mild   32 51.6   21 56.8
Moderate   16 25.8   14 37.8
Severe   1 1.6   1 2.7
Plaque Index 0 to 50%   12 19.4   7 19
51 to 75%   12 19.4   10 27
76 to 100%   38 61.2   20 54
CPI Health   5 8.1   3 8.1
Bleeding   8 12.9   3 8.1
Calculus   26 41.9   13 35.1
Pockets of 4-5 mm   17 27.4   13 35.1
Pockets over 6 mm   6 9.7   5 13.5
Table 3. Distribution of patients, 
according to periodontal variables 
observed.
(Table 4). Nevertheless, after multivariate analysis, only 
the source of medication, specifically phenytoin, presented 
significant association with gingival overgrowth (P=0.007) 
(Table 5).
Table 4. Bivariate analysis 
(α=25%) performed to verify 
the association between GO, 
demographic, drugs, and 
periodontal features in users of 
nifedipine or phenytoin (n=100).
Variable Category RP (α=5%) P
Income Up to one minimum wage 1.15 (0.94-1.40)
0.156
More than one minimum wage 1.00
Drug Phenytoin 1.22 (1.06-1.42)
0.007*
Nifedipine 1.00
Concentration Pattern 0.92 (0.70-1.21)
0.547
Over the pattern 1.00
Time of utilization Up to three years 0.88 (0.74-1.05)
0.160
More than three years 1.00
* Statistically significant.
Table 5. Multivariate analysis 
(Regression of Poisson – RP) to 
verify the association between GO, 
demographic and drug features   
in users of nifedipine or   
phenytoin (n=100).146  Rev. odonto ciênc. 2010;25(2):142-147
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Discussion
Calcium antagonists, such as nifedipine, are widely employed 
for the treatment of cardiovascular diseases or in patients 
submitted to dyalisis (11,12). The most important secondary 
side  effects  of  this  drug  are  hypotension,  headaches, 
flushness, dizziness, tremor, joint stiffness, peripheral edema, 
dermatitis, pruritis and urticaria (4). Besides these effects, 
DIGO is also related (12). Phenytoin (5-diphenilphenytoin) 
has been used to control seizure crisis in patients since its 
clinical introduction by Merritt & Putnam in 1938 (5). DIGO 
is a frequent side effect in users of this drug (14).
The population of this study was comprised of individuals with 
low schooling level and reduced family income, compatible 
with the profile of the population assisted by the Brazilian 
Primary Health Care System (15). In contrast with the majority 
of studies that deal with DIGO, where the studied population 
is selected in medical or dentistry centers, this study aimed 
to characterize, epidemiologically and demographically, the 
local population receiving nifedipine and/or phenytoin (10, 
16-19). As a result, this study presented some particularities 
such as the reduced number of teeth as inclusion criteria, due to 
the high grade of edentulism in the adult and elderly Brazilian 
population,  the  predominant  sample  of  this  study  (20). 
In addition, a high level of dental biofilm was observed in the 
majority of evaluated individuals, in their residences. When 
the dental exam is previously scheduled, the scores of dental 
biofilm may be lower, due to more careful oral hygiene than 
under normal circumstances (11).
In this study, a high prevalence of DIGO was observed 
associated with nifedipine (79%) and phenytoin (97.3%), 
with a predominance of mild DIGO. This result surpasses 
the mean DIGO incidence, as related in the literature for 
phenytoin (50%) and nipedipine (0.5 to 83%) (2,7,11,16,18). 
The large variation in the prevalence of DIGO in these studies 
may be due to variations in population characteristics, size 
sample, sample selection and methods employed to perform 
DIGO evaluation (5,16).
No significant relationship was found between DIGO and 
demographic features such as age, gender, scholarship level, 
or profession, after the adjustment to determine the risk 
potential. Regarding income, all the populations in this 
study can be considered to be homogeneous, reflecting the 
situation of the majority of the population of this region. In 
Brazil, individuals that work in manual jobs are more likely 
to receive lower salaries than those that work in commerce 
or education, for example.  This fact may have attenuated 
the strength of the association between income and the 
parameters measured in the present study. 
Generally, there was no correlation of DIGO with race, 
gender  and  age,  as  demonstrated  by  previous  studies, 
although this fact is not consensual (2,14,24). In addition, the 
association between DIGO and pharmacological variables 
such as dose, concentration and time of treatment was not 
observed, in agreement with previous studies (11,16,24,25). 
The attempt to associate doses, plasma and salivary levels, 
drug combinations, time of utilization with beta-blockers 
and phenytoin DIGO has presented contradictory results 
(2,5). It is believed that there is a minimum level of drugs 
necessary to lead to DIGO. This level may differ depending 
on the responsiveness of the patient (5). 
There are many reports of significant correlations between 
the presence and severity of DIGO induced by drugs and 
presence of biofilm, calculus, periodontal pockets, and the 
need for periodontal treatment and poor oral care (16,18).   
The bacterial dental biofilm level is strongly associated 
with  gingival  and  periodontal  disease  and  its  control   
has an important role in the control and prevention of   
DIGO (5,6). Nevertheless, even in the presence of the high 
biofilm levels and CPI shown in this study, there was a lack 
of evidence of any association of these factors with DIGO, 
as demonstrated by other studies (11,25). In addition, while 
there is evidence of the relationship between plaque-induced 
inflammation and DIGO, the role of dental biofilm may 
only be to enhance the effects of this gingival alteration, as 
proposed previously (10). Despite the controversy results of 
the relation between periodontal variables and DIGO, the 
role of the dental professional is still important to perform 
early diagnostic and control of this alteration.
Even  with  a  large  prevalence  of  DIGO  in  the  studied 
population,  the  majority  did  not  perceive  any  gingival 
alteration. This may be due to the fact that mild or moderate 
overgrowth was more frequently found, not affecting the 
esthetics or function in these patients. Nevertheless, even 
among patients who perceived the presence of DIGO, less 
than half sought professional dental care.
Considering  the  high  prevalence  of  DIGO,  induced  by 
nifedipine  and  phenytoin,  as  pointed  out  in  this  study, 
and the fact that these drugs are widely employed to treat 
cardiovascular and neurological illness, the role of dental 
professionals in the Primary Health Care System is very 
important.  These  professionals  must  be  stimulated  to 
carefully review the medical history of patients using (or that 
have used) drugs with DIGO-inducing potential. In addition, 
a detailed oral examination is imperative to observe the 
morphological alterations associated with these drugs (5).  In 
a recent study, it was demonstrated that the inclusion of an 
evaluation of oral health for patients assisted by preventive 
medical programs is an important strategy to target those at 
a risk of oral disease, taking into account the low perceptive 
capacity for dental care and irregular visiting patterns that 
many people present (22). Moreover, the literature also 
reports evidence of association between oral health status 
and affects the general quality of life (23).
In summary, within the limits of the present study, it is 
possible to conclude that nifedipine- and phenytoin-induced 
GO prevalence is high among users of Primary Health Care 
System. However, this alteration is more associated with 
phenytoin. Demographic, pharmacological, and periodontal 
features did not influence DIGO in the observed population. 
The high prevalence of DIGO in phenytoin and nifedipine 
users emphasizes the importance of the dental professional 
in the diagnosis, control and treatment of this important side 
effect, mainly in the Primary Care Health System.   Rev. odonto ciênc. 2010;25(2):142-147  147
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